CD200 and breast cancer: Finally, we validated that RAD9A, HSPA1B, GATA2, IGF2R, CD200, ERCC8, and BCL11A genes are consistently dysregulated in the doxorubicin-induced human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) derived from breast cancer patients (Fig. 10).